Abgenix starts ABX-IL8 Phase IIa study in RA

ABGX began placebo-controlled U.S. Phase IIa testing of its ABX-IL8 human monoclonal antibody against IL-8 in 132 rheumatoid arthritis (RA) patients. The primary end point of the 12-week study is the ...